The CEOs of both Bristol-Myers Squibb (BMY 0.19%) and Teva Pharmaceutical Industries (TEVA 0.16%) have indicated that they're looking to make deals at the moment. In this video, Motley Fool health-care analyst David Williamson looks at both companies and how successful some of their recent mergers and acquisitions were. He also examines several possible takeover candidates and discusses just how likely each might be for an acquisition by BMY or TEVA. Finally, David tells investors which of the two he sees as stronger at the moment, and how this pricey bull market may affect the companies' decisions.
2014 Trend Alert: Health-Care M&A
By Dave Williamson – Jan 18, 2014 at 5:26PM
NYSE: BMY
Bristol Myers Squibb
Market Cap
$89B
Today's Change
(-0.19%) $0.09
Current Price
$43.74
Price as of October 24, 2025 at 2:09 PM ET
Are Bristol-Myers Squibb and Teva on the hunt for some M&A opportunities?
About the Author
The Motley Fool's Healthcare Analyst, I specialize in Pharma, Biotech, and how the ACA (Obamacare) is changing the business of healthcare in America. Follow me on Twitter for breaking stock news, policy thoughts, and misc musings...
Follow @motleydavid